Fired trans Dem campaigner urges followers ‘kill your local Republican’, vows ‘trans jihad’

 A transgender activist and former campaign volunteer for a Democratic congressional candidate in Wisconsin called for deadly violence against Republicans — and vowed to unleash “trans jihad” against the “animals” in the MAGA movement in a series of unhinged videos on social media.

In one such posting, Teha Delaruelle, who briefly volunteered on the campaign of Wisconsin Democratic Socialist Katrina deVille, who is also transgender, sits in front of a dry-erase board scrawled with “kill your local Republican” in black marker.

“We’re going to make this the moderate position for the state of Wisconsin,” Delaruelle says while pointing at the sick message.

5

Trans activist Teha Delaruelle called for violence against Republicans in a series of unhinged social media videos.Instagram/tehabbygal_

5

Delaruelle briefly worked as a volunteer for Democratic Socialist Katrina deVille, who is also transgender, but was removed when the candidate realized they were “deeply troubled” and “creating a dangerous situation” for the campaign.Getty Images for WisDemsIn another twisted video, Delaruelle, a biological male who identifies as female, declared, “Just a reminder, we are doing trans jihad,” with a superimposed trans flag in the foreground featuring an outstretched arm holding a rifle with what looks like Arabic writing above it.

“It’s about making the oppressor, the bigots, the animals that make up MAGA, for example, right? So for decades, everyone else, all the marginalized, minorities, we’ve had to be the ones that walk down the streets with anxiety, with fear, but no, no more, no, no, no, no, no, no more, folks,” Delaruelle states disjointedly in the recording.

“We’re gonna do the reverse. We’re gonna make it so that they will be the ones that have to walk down the streets in fear, anxiety and worry. And we’re not gonna make this like, oh, they gotta do this for like, a week or something, where they get really scared. No, this is their new reality. And it’s never gonna change,” the crazed activist pledges before ponderously holding up two fingers and saying “peace.”

In an equally deranged Substack post along the same theme from earlier this month, Delaruelle bemoans what he calls an ongoing “genocide” against “trans and queer folk,” and says the only way to meet the threat is to wage war.

5

Delaruelle encouraged followers to take up a “trans jihad” against the “animals” in the MAGA movement, vowing to make them live in fear.Instagram/tehabbygal_

“Society desires nothing less than our total extermination, therefore we must destroy their society. We must answer this call to a [sic] existential struggle, our jihad, our Trans Jihad.”

Reached by email Thursday morning, deVille said Delaruelle was a campaign volunteer for a “very short while” but was removed when it became apparent they were “deeply troubled,” and later blocked from all of her accounts and pages “because they were actively creating a dangerous situation around my campaign.”

5

A screengrab from a video from Katrina DeVille.TikTok/tehatealove

5

Katrina DeVille posted hateful messages on her social media pages.eX / TehaTeaTime

DeVille also denounced the former-volunteer’s alarming calls for violence against Republicans

“I want to be clear that I do not accept or condone violence or threats toward anyone and do not encourage violence, hate, or threats of any kind,” deVille said.

“The threats she has posed have also made my life more dangerous, and I understand first hand how awful this is, how awful it feels, and how absolutely unacceptable any of this is.”

“I also hope that she is able to get help and find peace, and that no one becomes hurt or endangered from this senseless situation.”

Delaruelle did not immediately respond to The Post’s requests for comment.

https://nypost.com/2026/07/02/us-news/fired-trans-dem-campaigner-calls-on-followers-to-kill-your-local-republican-and-vows-trans-jihad/

Carney to Keep North BC Tanker Ban as Alberta to Unveil Pipeline Proposal

 

Prime Minister Mark Carney announced a deal with British Columbia that keeps an oil tanker ban in place for Canada’s north coast, and commits billions of dollars in federal funding for energy, mining and transportation projects.

The move is meant to boost Premier David Eby’s top priorities for his province, but also serves to soften the blow of a more controversial announcement: Alberta’s bid to build a new crude oil pipeline through BC’s mountainous terrain.

https://www.bloomberg.com/news/articles/2026-07-02/carney-to-keep-north-bc-tanker-ban-as-alberta-to-unveil-pipeline-proposal

Insulet Recalls Omnipod Pods After Insulin-Delivery Failure Risk Identified, FDA Says

 his recall involves removing certain devices from where they are used or sold. The FDA has identified this recall as the most serious type. This device may cause serious injury or death if you continue to use it. The affected products and recommendations for what to do with the devices below have not changed. 

Affected Product

The FDA is aware that Insulet has issued a letter to affected customers recommending certain Omnipod Pods be removed from where they are used or sold. Affected devices:

• Omnipod 5 Automated Insulin Delivery System 
• Omnipod DASH Insulin Management System 
• Omnipod Insulin Management System (Omnipod Eros) 
• Full List of Affected Product

What to Do

Do not use Pods from affected lots. Check all Pods to determine if they are affected. If you are currently using a Pod from an affected lot, immediately change your Pod to resume insulin delivery. If you do not have enough Pods due to this issue, talk to your healthcare provider about other methods of insulin delivery.

On May 26, Insulet sent all affected customers a letter recommending the following actions:

• DO NOT use Pods from the affected lots. 
  • Check the lot number on your Pod tray lid, the Pod box or the Pod itself to determine if your Pods are affected. 
  • Follow Insulet’s instructions and pictures to help identify the lot number for your Pods 
  • Review the lot list to determine whether your Pod is impacted.  
  • All Pods within a single box will be from a single lot and if the lot is affected, do not use any of those Pods. 
• If your Pods are impacted: 
  • Discontinue use of any impacted Pod immediately. If the Pod you are currently using is from an affected lot, it is important that you immediately change your Pod to resume insulin delivery. When changing your Pod, confirm that the new Pod is not from an affected lot.  
  • Follow the instructions provided by Insulet in their customer email to acknowledge that your Pod is impacted and request a replacement.  
  • For additional information, call Insulet’s Product Support phone line at 1-800-641-2049, available 24/7. 
• Users will receive a return kit with clear instructions on how to send back any unused affected Pods.  
• Always check the expiration date before using a Pod. Do not use any Pod that is past its expiration date, as expired Pods may not function as intended. 
• If your Pod supply is depleted due to this issue, consult with your healthcare provider for alternative means of insulin delivery while waiting for Pods to be replaced. Always follow your healthcare provider's guidance on appropriate glucose monitoring. 

Reason for Recall

Insulet identified that some Pods from specific lots may have a small tear in the tubing (cannula) just above the skin, between the Pod and the point where the cannula enters the body.  If this occurs, insulin may leak outside of the Pod instead of being fully delivered into the body as intended, potentially leading to under-delivery of insulin.  If you are using an affected Pod, you may notice wetness on your skin or Pod adhesive or detect the smell of insulin. However, in some cases, this may be difficult to detect and may go unnoticed.  

If insulin leakage occurs, your blood glucose levels may rise and may not respond as expected to insulin delivery. If using Omnipod 5, and it is in Automated Mode, this could trigger an Automated Delivery Restriction alert, advising you to troubleshoot. However, this issue may happen without triggering any alert, meaning you could receive less insulin than needed without realizing it. Do not rely only on Pod alerts to know if something is wrong.

If insulin is not delivered properly, you may experience high blood glucose levels due to under-delivery of insulin. In the most severe cases, prolonged and persistent high blood glucose levels can lead to diabetic ketoacidosis (DKA), a serious medical condition that requires prompt medical treatment and can be life-threatening if not treated.

Note that this issue does not affect continuous glucose monitoring (CGM) systems or CGM readings.

As of May 20, Insulet has reported 24 serious injuries and no deaths associated with this issue.

https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/insulin-pump-recall-insulet-removes-omnipod-pods

Nuclear Reactor Powers Nvidia AI Chip in US First

 alar Atomics Inc., a California-based nuclear startup, generated power from an advanced reactor to run an Nvidia Corp. AI chip. While just a trickle of electricity was produced, it's the first time a next-gen reactor has done so in the US.

Valar's Ward 250 reactor was connected to the Nvidia Blackwell chip during a demonstration Wednesday at the company's site in Utah, and used to temporarily host a website. The two companies also announced an agreement to jointly explore ways to develop nuclear-powered AI systems.

The latest step follows the reactor reaching "criticality" last month, marking the start of a self-sustaining fission reaction. Valar is part of a wave of companies developing next-generation nuclear technologies that use new materials and designs intended to improve safety and performance. However, the industry is still in its early stages, and no US advanced reactors are commercially available.

https://finance.yahoo.com/technology/ai/articles/nuclear-firm-first-us-produce-211439173.html

Google: Action taken against NetNut's malicious network

 Google LLC announced in a blog post on Thursday that, in coordination with the FBI, Lumen, and others, it took action against the NetNut residential proxy network, also known as Popa.

To disrupt the proxy network, Google accounts and associated Google services used by NetNut for malware command and control (C2) were disabled, technical intelligence on NetNut software development kits (SDKs) and backend C2 infrastructure was shared, and Google's Play Protection "automatically warned users and disabled applications known to incorporate NetNut SDKs."

The tech giant stated that the coordinated actions significantly degraded the proxy network, "reducing the available pool of devices for the proxy operator by millions." Google Threat Intelligence Group (GTIG) estimated that NetNut's network size is at least 2 million devices.

https://breakingthenews.net/Article/Google:-Action-taken-against-NetNut's-malicious-network/66625044

Colorado's pathfinder medicine price-cap move stalls

 A federal judge in the US has sided with Amgen in a dispute over a price cap imposed by the state of Colorado on its blockbuster immunology drug Enbrel.

In a move viewed as a test of states' ability to impose drug pricing controls, the Colorado Prescription Drug Affordability Review Board (PDAB) placed a $600-per-week price cap on the drug last October for a standard weekly dose – about $31,000 per year – but almost 50% lower than typical prices in the state in 2023.

The first-of-its-kind price cap has been overturned by Judge Daniel Domenico in the Denver federal court, who accepted Amgen's request to impose a preliminary injunction on the cap – known as an upper payment limit – on the grounds that it is pre-empted by federal law and violates due process and commercial rights.

In its lawsuit, Amgen claimed the upper payment limit for Enbrel (etanercept), a widely used TNF inhibitor for diseases like rheumatoid arthritis, would cause it to "suffer substantial, irreparable harm."

The company made almost $2 billion from the brand last year in the US, out of global sales of $2.23 billion, although, sales have been falling steadily from a peak of more than $8.5 billion in recent years since the start of biosimilar competition overseas. In the US, biosimilars have been approved, but are blocked from launch by ongoing patent litigation and are not expected to reach the market until 2029.

"Both parties make important, and persuasive, policy arguments," wrote Domenico in his ruling on the case.

"Colorado is undoubtedly correct that the price of many beneficial medications is difficult, if not impossible, for many citizens to afford," he added. "Amgen is correct that the development of the new medications many of us benefit from requires that profits from the few successful ones be large enough to cover not only their own development, but that of dozens of failed experiments."

He pointed out, however, that these "policy issues" are not relevant to the case under consideration, as "under binding Federal Circuit precedent, caps on the price of patented drugs like Enbrel are preempted by federal law."

The PDAB had contended that Amgen would not be harmed by the cap because of the convoluted way Enbrel is paid for at various levels of the supply chain, which is typical of the US market and makes it hard to tease out accurate pricing data.

Domenico wrote that drug pricing is remarkable for its "puzzling opacity," but added that it is "not necessary to unravel the entire system to understand that, as a result of Colorado's cap, Amgen will receive less money from its wholesalers and will fare more poorly in negotiations with other purchasers in Colorado and elsewhere."

He advised the PDAB to try to reduce Enbrel's price through subsidies or negotiations to lower prices, as has been done by the federal government through the Medicare system.

The preliminary injunction pauses the cap, which had been due to come into effect at the start of next year, while the underlying lawsuit proceeds.

https://pharmaphorum.com/news/colorados-pathfinder-medicine-price-cap-move-stalls

Almost half of dementia cases could be prevented, says study

 A study has found that nearly half of all cases of dementia are avoidable with lifestyle changes, but public health campaigns have proven to be ineffective at driving change.

The review of a dozen national, population-level awareness campaigns targeting modifiable risk factors like physical inactivity, smoking, low education, and social isolation – published in The Lancet Healthy Longevity journal – has found they have broad reach, but deliver only marginal benefits.

The researchers behind the work, from Curtin University in Australia, say that more engaging, personalised, and community-driven approaches are needed to genuinely influence behaviour and reduce dementia risk.

The results of the analysis reveal "a clear gap between what people know and what they do," according to the researchers, led by Professor Mario Siervo from Curtin's School of Population Health.

"Up to 45% of dementia cases are linked to modifiable factors we can change, such as our lifestyle, health status, and environment," he said. "But simply telling people what those risks are isn't enough; awareness campaigns are important, but on their own they rarely lead to meaningful or lasting behaviour change."

Interventions requiring active engagement – such as online courses, e-learning programmes, and community-based approaches – produce stronger behavioural effects than passive information-only approaches.

When combined with personalised risk profiling showing individuals how their lifestyle affects their dementia risk, the approach could deliver a 26% improvement in modifiable risk factor status over three years, they suggest.

Body composition study

In a separate study, published in the journal Clinical Nutrition, Siervo and colleagues explored other modifiable risk factors for dementia, specifically muscle strength and body composition.

They followed nearly 500,000 adults with sarcopenic obesity - defined as the combination of excess body fat and low muscle mass and strength - for more than a decade, and found a 30% increased risk of dementia, while obesity on its own was not associated with increased dementia risk if muscle strength was preserved.

Study co-author Prof Blossom Stephen, chair in dementia at Curtin's enAble Institute, said the results provide further evidence that dementia risk is modifiable, and not an unavoidable part of ageing.

However, "even when people are aware of the risks, barriers such as time, cost, and motivation can prevent them from making changes to their lifestyle," she added.

"We need to combine broad public messaging with targeted support that helps people take action. That means investing in programmes that are accessible, culturally relevant, and designed with communities, not just delivered to them."

https://pharmaphorum.com/news/almost-half-dementia-cases-could-be-prevented-says-study